Transcranial Pulse Stimulation for Alzheimer's Disease
ConditionAlzheimer Dementia (AD)
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age60-90
SponsorChinese University of Hong Kong
About this trial
TPS is a non-invasive therapeutic modality that uses focused, low-energy pulse stimulation to stimulate tissue regeneration and reduce inflammation. In the context of neurological disorders, it is hypothesized that TPS can modulate neuronal activity, enhance synaptic plasticity, and reduce neuroinflammation. It is a relatively new application in neurological disease treatment and is still under intense investigation.
Eligibility criteria
Qualifiers
Adults who have been clinically diagnosed with Alzheimer's Disease in the early stage 2-6a according to the Functional Assessment Staging Test (In Appendix A)
The mental capacity to give informed consent for research is made by an experienced geriatrician based on Appendix A.
Aged 60-90 years old.
Able to make informed consent under assistance, which is witnessed and signed by a family caregiver.
Disqualifiers
Cannot understand Chinese.
Mentally incapacitated, unable to provide informed consent
Inability to remain still for 30 minutes
Lack of available family caregiver to answer questionnaires
Trial design
Treatments tested in this trial
- transcranial pulse stimulation (TPS)
- transcranial pulse stimulation (TPS-Sham)
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Chinese University of Hong Kong
Lead sponsor
Asia Pacific Institute of Healthy ageing
Collaborator
Associated medical supplies company limited
Collaborator
Dongguan University of Technology
Collaborator
SuZhou Engin Bio-medical Electronics.Co.Ltd.
Collaborator
Source ClinicalTrials.gov